TR201721505A2 - Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon - Google Patents

Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon Download PDF

Info

Publication number
TR201721505A2
TR201721505A2 TR2017/21505A TR201721505A TR201721505A2 TR 201721505 A2 TR201721505 A2 TR 201721505A2 TR 2017/21505 A TR2017/21505 A TR 2017/21505A TR 201721505 A TR201721505 A TR 201721505A TR 201721505 A2 TR201721505 A2 TR 201721505A2
Authority
TR
Turkey
Prior art keywords
linagliptin
metformin
combination
present
composition
Prior art date
Application number
TR2017/21505A
Other languages
English (en)
Inventor
Türkyilmaz Ali̇
Pehli̇van Akalin Nur
Ergun Donmez Merve
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/21505A priority Critical patent/TR201721505A2/tr
Priority to EP18913688.0A priority patent/EP3731837A4/en
Priority to PCT/TR2018/050857 priority patent/WO2019194773A2/en
Publication of TR201721505A2 publication Critical patent/TR201721505A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, linagliptin, metformin ve en az bir farmasötik olarak kabul edilebilir eksipiyan içeren katı oral farmasötik kompozisyon ile ilgilidir. Ayrıca mevcut buluş, söz konusu kompozisyonu hazırlama yöntemi de sunmaktadır.
TR2017/21505A 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon TR201721505A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
EP18913688.0A EP3731837A4 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin
PCT/TR2018/050857 WO2019194773A2 (en) 2017-12-25 2018-12-21 The combination comprising linagliptin and metformin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon

Publications (1)

Publication Number Publication Date
TR201721505A2 true TR201721505A2 (tr) 2019-07-22

Family

ID=67900634

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/21505A TR201721505A2 (tr) 2017-12-25 2017-12-25 Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon

Country Status (3)

Country Link
EP (1) EP3731837A4 (tr)
TR (1) TR201721505A2 (tr)
WO (1) WO2019194773A2 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7689825B2 (ja) * 2020-12-18 2025-06-09 日本ジェネリック株式会社 熱安定性に優れたリナグリプチン含有医薬組成物
WO2022173406A1 (en) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
JP2022171507A (ja) * 2021-04-30 2022-11-11 日本ジェネリック株式会社 安定性に優れたリナグリプチン含有製剤
WO2023002036A1 (en) * 2021-07-22 2023-01-26 Krka, D.D., Novo Mesto Process for preparing a pharmaceutical composition comprising linagliptin and metformin hydrochloride
EP4422615A4 (en) * 2021-10-28 2025-09-17 Texas A & M Univ Sys COMPOSITIONS OF STABLE METFORMIN AND SIMILAR DRUG PRODUCTS WITH CONTROL OF NITROSO IMPURITIES
WO2023163510A1 (ko) * 2022-02-23 2023-08-31 주식회사 제뉴원사이언스 리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2014080383A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
EP2848242A1 (en) * 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
WO2015107536A2 (en) 2013-12-09 2015-07-23 Intas Pharmaceuticals Limited Fixed dose combination comprising linagliptin and metformin hci
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof

Also Published As

Publication number Publication date
EP3731837A4 (en) 2021-06-30
WO2019194773A3 (en) 2019-12-12
EP3731837A2 (en) 2020-11-04
WO2019194773A2 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
IL289763A (en) Compounds, pharmaceutical compounds and methods for preparing compounds and their use
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
MY197700A (en) Compounds useful for inhibiting cdk7
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
MX2017016802A (es) Formulaciones farmaceuticas.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
JOP20170137B1 (ar) صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX393915B (es) Nuevas formulaciones orales de belinostat.
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
JOP20230099A1 (ar) تركيبات صيدلية
IN2014MU00859A (tr)
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.